Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04467723 · ClinicalTrials.gov registry record · Phase 1
Combination of Atezolizumab and Pirfenidone in Second-line and Beyond NSCLC
A Phase 1 study of NSCLC Stage IV and NSCLC, Recurrent, sponsored by University of Kansas Medical Center.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 25
- Enrollment target
- 2
- Study locations
NCT04467723 is a Phase 1 study of NSCLC Stage IV and NSCLC, Recurrent that is actively recruiting participants, run by University of Kansas Medical Center. The registered enrollment target is 25 participants, below the 119-participant average among 6 other NSCLC Stage IV trials with a reported enrollment target (79% lower). The trial reports 2 study locations across 1 state.
The verdict
NCT04467723, a Phase 1 study of NSCLC Stage IV and NSCLC, Recurrent, is actively recruiting participants, sponsored by University of Kansas Medical Center.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 25 participants
- Enrollment target
- 2
- Study locations
Study Summary
The purpose of this study is to see if adding pirfenidone to atezolizumab will increase anti tumor activity and reduce treatment resistance in stage 4 and recurrent non- small cell lung cancer participants.
Conditions Studied
Interventions
- DRUG Atezolizumab
Study Locations (2)
Kansas
- The University of Kansas Cancer Center (KUCC) - Fairway
- The University of Kansas Cancer Center, Westwood Campus - Kansas City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2022-05-18 |
| Est. Completion | 2027-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04467723
The ClinicalTrials.gov registry entry for NCT04467723 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 25 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 119-participant average among 6 other NSCLC Stage IV trials with a reported enrollment target (79% lower). The listed sponsor is University of Kansas Medical Center, which has 408 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with NSCLC Stage IV appearing as the primary indexed condition, and to 1 intervention - of which Atezolizumab is the first listed.
NCT04467723 reports 2 study locations spanning 1 distinct geographic area - top geographies include Kansas.
Frequently Asked Questions
What is clinical trial NCT04467723 about?
NCT04467723 is a clinical study titled "Combination of Atezolizumab and Pirfenidone in Second-line and Beyond NSCLC". The purpose of this study is to see if adding pirfenidone to atezolizumab will increase anti tumor activity and reduce treatment resistance in stage 4 and recurrent non- small cell lung cancer participants.
What is the current status of trial NCT04467723?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 25 participants. The study started on 2022-05-18. Estimated completion is 2027-08.
What conditions does trial NCT04467723 study?
This clinical trial studies the following conditions: NSCLC Stage IV, NSCLC, Recurrent.
What interventions are being tested in trial NCT04467723?
The interventions under investigation include: Atezolizumab (DRUG).
Who is sponsoring clinical trial NCT04467723?
This trial is sponsored by University of Kansas Medical Center, which has 408 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04467723 being conducted?
This trial has 2 study locations across Kansas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for NSCLC Stage IV
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Peptide Vaccine To Prevent Acquired Resistance In Patients With Advanced ALK+ NSCLC
RECRUITING · Phase 1
-
ResQ201A: Clinical Trial Of N-803 Plus TISLELIZUMAB And DOCETAXEL Versus DOCETAXEL Monotherapy In Participants With Advanced Or Metastatic Non-Small Cell Lung Cancer
RECRUITING · Phase 3
-
Using Ex Vivo Tumoroids To Predict Immunotherapy Response In NSCLC
RECRUITING
-
A Study of Targeted Radiation Therapy in People With Non-Small Cell Lung Cancer (NSCLC)
RECRUITING · Phase 2
-
Plasma-Adapted First-Line Pembro In NSCLC
ACTIVE NOT RECRUITING · Phase 2
-
Randomized Study of Stereotactic Body Radiation Therapy (SBRT) in Patients With Oligoprogressive Metastatic Cancers of the Breast and Lung
ACTIVE NOT RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.